US 10,376,506 B2
Use of an opioid receptor antagonist with kappa-activity and vortioxetine for treatment of depressive disorder with melancholic features
Connie Sanchez Morillo, West Milford, NJ (US); and Gennady N. Smagin, Newark, DE (US)
Assigned to H. LUNDBECK A/S, Valby (DK)
Appl. No. 15/105,701
Filed by H. Lundbeck A/S, Valby (DK)
PCT Filed Dec. 18, 2014, PCT No. PCT/EP2014/078515
§ 371(c)(1), (2) Date Jun. 17, 2016,
PCT Pub. No. WO2015/091833, PCT Pub. Date Jun. 25, 2015.
Claims priority of application No. 2013 00710 (DK), filed on Dec. 20, 2013; and application No. 2014 00590 (DK), filed on Oct. 16, 2014.
Prior Publication US 2016/0310488 A1, Oct. 27, 2016
Int. Cl. A61K 31/4965 (2006.01); A61K 31/44 (2006.01); A61K 31/495 (2006.01); A61K 31/485 (2006.01)
CPC A61K 31/495 (2013.01) [A61K 31/485 (2013.01)] 14 Claims
OG exemplary drawing
 
1. A method of treating a patient having depressive disorder with melancholic features, comprising administering a therapeutically effective amount of an opioid antagonist with κ-activity to the patient, wherein said administered opioid antagonist is nalmefene, and wherein said method further comprises administering a therapeutically effective amount of vortioxetine to the patient.